Bezafibrate

Chemical name

2-[4-[2-[(4-Хлорбензоил)ам��но]этил]фенокси]-2-мет��лпропановая acid

Gross

C19-H20-Cl-N-O4

Characteristics

Derived fibroeva acid.

Of drugs

The drugs-gipolipidemicescoe, antiateroskleroticescoe, antiagregatine, gipoglikemicescoe. Increases activity lipoproteidna lipase, intensified catabolised triglycerides in lipoproteidah very low and low density. Stops peripheral lipolysis and reduces liver extraction of free fatty acids and triglycerides synthesis in the liver. Oppressing education and increases LPONP Cl. Suppress activity CoA reductase reduces mevalonata synthesis. Reducyruet level of triglycerides, total cholesterol and to a lesser extent reasonable cholesterol increases the cholesterol level LPVP, particularly LPVP_3 and LPVP_2. Impact agregatia platelets and blood viscosity. In appointing 400 mg once a day in the extended form in patients with giperholesterinemiei slows the progression of atherosclerosis, reducing the frequency deterioration coronary blood among high-risk groups, to improve lipid profile and reduce fibrinoguena in blood.

Indications

Giperlipidemia predominantly with the гипертриглицеридемие й (types IV and V), with the ineffectiveness of diets and the high risk of pancreatitis (triglyceride level of more than 2,000 mg%), IIB giperlipidemia type, including in patients with diabetes and in violation of tolerance to carbohydrates with metabolic syndrome.

Contraindications

Hypersensitivity and the paucity of the liver, primary biliary cirrhosis, diseases of the gallbladder, heavy human kidney functions, pregnancy, breast-feeding (at the end of treatment), the period of growth.

Side-Effects

Diarrhoeal events (nausea, anorexia, pain in the abdomen, pregnant stomach, diarrhoea), raising transaminaz, changing picture of peripheral blood (anaemia, lakopenia) holetaz, miopatia with pain and rigidity of large groups of muscles rabdomioliz increase activity CPK, alopecia, impotence, allergic reactions.

Patient interaction

Potenziruet the anti proximity. Lovastatin and other inhibitors CoA reductase increase the risk rabdomioliza.

Precautions

In the long admission requires continuous monitoring cell composition peripheral blood transaminaz activity. Increased activity ALT twice or more a cause of the drug, as well as the emergence of complaints of muscle pain and muscle weakness. There should be patient abdominal cavity to avoid lithogenesis in the gall bladder and the litogennogo a coma. The treatment is recommended that the diet.

Dosing and Administration

Inside, in the 0.2 g three times daily, long repetitive courses; Possibly reducing dose to 0.4 g / sut.

Directory → Metaboliki → Lipid means → Fibrata → Bezafibrate